<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#964b00"},
{source: "3: Additional ", target: "3: presently known", fill: "#964b00"},
{source: "3: presently known", target: "3: immaterial may also impair", fill: "#964b00"},
{source: "3: immaterial may also impair", target: "3: operations", fill: "#964b00"},
{source: "3: Additional ", target: "5: future profitability", fill: "#860111"},
{source: "5: future profitability", target: "5: common stock", fill: "#860111"},
{source: "5: common stock", target: "5: speculative investment", fill: "#860111"},
{source: "5: future profitability", target: "10: become profitable", fill: "#966"},
{source: "10: become profitable", target: "10: remain profitable on", fill: "#966"},
{source: "10: remain profitable on", target: "10: continuing basis", fill: "#966"},
{source: "10: become profitable", target: "14: manufacture", fill: "#f8de7e"},
{source: "14: manufacture", target: "14: marketing efforts", fill: "#f8de7e"},
{source: "14: marketing efforts", target: "14: Embosphere Microsphere ", fill: "#f8de7e"},
{source: "14: Embosphere Microsphere ", target: "14: indications as well as", fill: "#f8de7e"},
{source: "14: indications as well as", target: "14: development activities", fill: "#f8de7e"},
{source: "14: development activities", target: "14: administrative costs", fill: "#f8de7e"},
{source: "14: manufacture", target: "15: cash requirements may vary materially from", fill: "#a4dded"},
{source: "15: cash requirements may vary materially from", target: "15: without limitation", fill: "#a4dded"},
{source: "15: without limitation", target: "15: generate from sales", fill: "#a4dded"},
{source: "15: generate from sales", target: "15: particular from", fill: "#a4dded"},
{source: "15: particular from", target: "15: regulatory", fill: "#a4dded"},
{source: "15: regulatory", target: "15: development efforts cost", fill: "#a4dded"},
{source: "15: development efforts cost", target: "15: testing costs", fill: "#a4dded"},
{source: "15: testing costs", target: "15: development programs competitive advances", fill: "#a4dded"},
{source: "15: development programs competitive advances", target: "15: regulatory review", fill: "#a4dded"},
{source: "15: regulatory review", target: "15: markets acceptance", fill: "#a4dded"},
{source: "15: markets acceptance", target: "15: approved products", fill: "#a4dded"},
{source: "15: cash requirements may vary materially from", target: "16: incur additional costs", fill: "#e48400"},
{source: "16: incur additional costs", target: "16: ongoing research", fill: "#e48400"},
{source: "16: ongoing research", target: "16: manufacturing laboratory", fill: "#e48400"},
{source: "16: manufacturing laboratory", target: "16: administrative functions as well as", fill: "#e48400"},
{source: "16: administrative functions as well as", target: "16: further market development", fill: "#e48400"},
{source: "16: further market development", target: "16: commercialization efforts", fill: "#e48400"},
{source: "16: incur additional costs", target: "20: cannot fund", fill: "#c54b8c"},
{source: "20: cannot fund", target: "20: new products through cash", fill: "#c54b8c"},
{source: "20: new products through cash", target: "20: generated from existing operations", fill: "#c54b8c"},
{source: "20: generated from existing operations", target: "20: cannot raise", fill: "#c54b8c"},
{source: "20: cannot raise", target: "20: capital expenditures scale back", fill: "#c54b8c"},
{source: "20: capital expenditures scale back", target: "20: development", fill: "#c54b8c"},
{source: "20: development", target: "20: others products", fill: "#c54b8c"},
{source: "20: others products", target: "20: technologies", fill: "#c54b8c"},
{source: "20: technologies", target: "20: otherwise would seek", fill: "#c54b8c"},
{source: "20: otherwise would seek", target: "20: commercialize ourselves", fill: "#c54b8c"},
{source: "20: cannot fund", target: "33: widespread market acceptance", fill: "#49796b"},
{source: "33: widespread market acceptance", target: "33: microsphere", fill: "#49796b"},
{source: "33: microsphere", target: "33: prospects will", fill: "#49796b"},
{source: "33: prospects will", target: "33: seriously harmed", fill: "#49796b"},
{source: "33: widespread market acceptance", target: "34: microspheres", fill: "#f8de7e"},
{source: "34: microspheres", target: "34: based on new technologies", fill: "#f8de7e"},
{source: "34: based on new technologies", target: "34: therapeutic approaches", fill: "#f8de7e"},
{source: "34: microspheres", target: "36: In November ", fill: "#ad6f69"},
{source: "36: In November ", target: "36: embolization", fill: "#ad6f69"},
{source: "36: embolization", target: "36: uterine fibroids", fill: "#ad6f69"},
{source: "36: In November ", target: "55: September ", fill: "#20b2aa"},
{source: "55: September ", target: "55: defendant", fill: "#20b2aa"},
{source: "55: defendant", target: "55: liability lawsuit", fill: "#20b2aa"},
{source: "55: liability lawsuit", target: "55: both eyes as", fill: "#20b2aa"},
{source: "55: both eyes as", target: "55: product during", fill: "#20b2aa"},
{source: "55: product during", target: "55: nasal angiofibroma embolization", fill: "#20b2aa"},
{source: "55: September ", target: "56: product liability", fill: "#e9967a"},
{source: "56: product liability", target: "56: adequate product liability insurance then", fill: "#e9967a"},
{source: "56: adequate product liability insurance then", target: "56: significant monetary damages", fill: "#e9967a"},
{source: "56: significant monetary damages", target: "56: successful product liability", fill: "#e9967a"},
{source: "56: product liability", target: "79: Acceptance ", fill: "#353839"},
{source: "79: Acceptance ", target: "79: community", fill: "#353839"},
{source: "79: community", target: "79: distinctive characteristics", fill: "#353839"},
{source: "79: distinctive characteristics", target: "79: benefits safety clinical efficacy", fill: "#353839"},
{source: "79: benefits safety clinical efficacy", target: "79: costeffectiveness", fill: "#353839"},
{source: "79: costeffectiveness", target: "79: products compared", fill: "#353839"},
{source: "79: products compared", target: "79: traditional methods", fill: "#353839"},
{source: "79: traditional methods", target: "79: competitors", fill: "#353839"},
{source: "79: competitors", target: "79: on training healthcare professionals", fill: "#353839"},
{source: "79: on training healthcare professionals", target: "79: application", fill: "#353839"},
{source: "79: Acceptance ", target: "173: key stockholders beneficially", fill: "#8e4585"},
{source: "173: key stockholders beneficially", target: "173: significant amount", fill: "#8e4585"},
{source: "173: significant amount", target: "173: exert control over us", fill: "#8e4585"},
{source: "173: key stockholders beneficially", target: "174: As of March ", fill: "#d6cadd"},
{source: "174: As of March ", target: "174: Sepracor Inc or Sepracor ", fill: "#d6cadd"},
{source: "174: Sepracor Inc or Sepracor ", target: "174: affiliated", fill: "#d6cadd"},
{source: "174: affiliated", target: "174: beneficially", fill: "#d6cadd"},
{source: "174: beneficially", target: "174: outstanding common stock respectively", fill: "#d6cadd"},
{source: "174: outstanding common stock respectively", target: "174: common stock issuable upon", fill: "#d6cadd"},
{source: "174: common stock issuable upon", target: "174: preferred stock", fill: "#d6cadd"},
{source: "174: preferred stock", target: "174: stockholders", fill: "#d6cadd"},
{source: "174: As of March ", target: "START_HERE", fill: "#d6cadd"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Paper Packaging</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Censorship</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Glass_microsphere">Glass microsphere</a></td>
      <td>Glass microspheres are microscopic spheres of glass manufactured for a wide variety of uses in research, medicine, consumer goods and various industries. Glass microspheres are usually between 1 and 1000 micrometers in diameter, although the sizes can range from 100 nanometers to 5 millimeters in diameter.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Expandable_microsphere">Expandable microsphere</a></td>
      <td>Expandable microspheres are microscopic spheres comprising a thermoplastic shell encapsulating a low boiling point liquid hydrocarbon. When heated to a temperature high enough to soften the thermoplastic shell, the increasing pressure of the hydrocarbon will cause the microsphere to expand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sirtex">Sirtex</a></td>
      <td>Sirtex Medical Limited is a medical device company, providing a radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres.  Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany and Singapore.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy">Selective internal radiation therapy</a></td>
      <td>Selective internal radiation therapy (SIRT), also known as transarterial radioembolization (TARE), radioembolization or intra-arterial microbrachytherapy is a form of radiation therapy used in interventional radiology to treat cancer. It is generally for selected patients with surgically unresectable cancers, especially hepatocellular carcinoma or metastasis to the liver.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Embolization">Embolization</a></td>
      <td>Embolization refers to the passage and lodging of an embolus within the bloodstream. It may be of natural origin (pathological), in which sense it is also called embolism, for example a pulmonary embolism; or it may be artificially induced (therapeutic), as a hemostatic treatment for bleeding or as a treatment for some types of cancer by deliberately blocking blood vessels to starve the tumor cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_liability_insurance">Professional liability insurance</a></td>
      <td>Professional liability insurance (PLI), also called professional indemnity insurance (PII) but more commonly known as errors &amp; omissions (E&amp;O) in the US, is a form of liability insurance which helps protect professional advice- and service-providing individuals and companies from bearing the full cost of defending against a negligence claim made by a client, and damages awarded in such a civil lawsuit. \nThe coverage focuses on alleged failure to perform on the part of, financial loss caused by, and error or omission in the service or product sold by the policyholder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strict_liability">Strict liability</a></td>
      <td>In  criminal  and  civil law, strict liability is a standard of liability under which a person is legally responsible for the consequences flowing from an activity even in the absence of fault or criminal intent on the part of the defendant.\nUnder the strict liability law, if the defendant possesses anything that is inherently dangerous, as specified under the "ultrahazardous" definition, the defendant is then strictly liable for any damages caused by such possession, no matter how careful the defendant is safeguarding them.In the field of torts, prominent examples of strict liability may include product liability, abnormally dangerous activities (e.g., blasting), intrusion onto another's land by livestock, and ownership of wild animals.Other than activities specified above (like ownership of wild animals, etc), US courts also consider the following activities as "ultrahazardous":\nstoring flammable liquids in quantity in an urban area\npile driving\nblasting\ncrop dusting\nfumigation with cyanide gas\nemission of noxious fumes by a manufacturing plant located in a settled area\nlocating oil wells or refineries in populated communities\ntest firing solid-fuel rocket motors.On the other hand, US courts rule the following activities as not "ultrahazardous": parachuting, drunk driving, maintaining power lines, and letting water escape from an irrigation ditch.Traditional criminal offenses that require no element of intent (mens rea) include statutory rape and felony murder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tort_reform">Tort reform</a></td>
      <td>Tort reform refers to changes in the civil justice system in common law countries that aim to reduce the ability of plaintiffs to bring tort litigation (particularly actions for negligence) or to reduce damages they can receive. Such changes are generally justified under the grounds that litigation is an inefficient means to compensate plaintiffs; that tort law permits frivolous or otherwise undesirable litigation to crowd the court system; or that the fear of litigation can serve to curtail innovation, raise the cost of consumer goods or insurance premiums for suppliers of services (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Self-driving_car_liability">Self-driving car liability</a></td>
      <td>Increases in the use of autonomous car technologies (e.g., advanced driver-assistance systems) are causing incremental shifts in the responsibility of driving, with the primary motivation of reducing the frequency of traffic collisions. Liability for incidents involving self-driving cars is a developing area of law and policy that will determine who is liable when a car causes physical damage to persons or property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automobile_products_liability">Automobile products liability</a></td>
      <td>When a person makes a claim for personal injury damages that have resulted from the presence of a defective automobile or component of an automobile, that person asserts a product liability claim. That claim may be against the automobile's manufacturer, the manufacturer of a component part or system, or both, as well as potentially being raised against companies that distributed, sold or installed the part or system that is alleged to be defective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Corporate_finance">Corporate finance</a></td>
      <td>Corporate finance is the area of finance that deals with sources of funding, the capital structure of corporations, the actions that managers take to increase the value of the firm to the shareholders, and the tools and analysis used to allocate financial resources. The primary goal of corporate finance is to maximize or increase shareholder value.Correspondingly, corporate finance comprises two main sub-disciplines.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder_rights_plan">Shareholder rights plan</a></td>
      <td>A shareholder rights plan, colloquially known as a "poison pill", is a type of defensive tactic used by a corporation's board of directors against a takeover.\nIn the field of mergers and acquisitions, shareholder rights plans were devised in the early 1980s as a way to prevent takeover bids by taking away a shareholder's right to negotiate a price for the sale of shares directly.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>The risks     described below are not the <font color="blue">only ones facing</font> our company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks     not <font color="blue">presently known</font> to us or that we deem <font color="blue">immaterial may also impair</font> our     business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">following risks could materially <font color="blue">adversely</font></font>     affect our business, operating results and <font color="blue">financial condition</font> and could     result in a complete loss of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Future Profitability, Our Financial Results and Need     For Financing       <font color="blue">Because  </font>we  have  a history of losses and our <font color="blue">future <font color="blue">profitability</font></font> is     uncertain, our <font color="blue">common stock</font> is a speculative <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We  have  incurred  operating  losses  since  our inception and, as of     <font color="blue">December </font>31,  2005, had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font> dlra78dtta80     million</td>
    </tr>
    <tr>
      <td>We expect to spend substantial funds to <font color="blue">continue research</font> and     <font color="blue">product testing</font>, to maintain sales, marketing, quality control, <font color="blue">regulatory</font>,     <font color="blue">manufacturing</font>  and  <font color="blue">administrative</font>  <font color="blue">capabilities</font> and for other general     <font color="blue">corporate purposes</font></td>
    </tr>
    <tr>
      <td>We expect to continue to incur operating losses in 2006,     as we continue our research, <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> efforts</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>If we do <font color="blue">become profitable</font>, we may not     <font color="blue">remain profitable on</font> a <font color="blue">continuing basis</font></td>
    </tr>
    <tr>
      <td>Our failure to become and remain     <font color="blue">profitable would depress</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font> and impair our     ability to <font color="blue">raise capital</font> and expand, diversify or continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to need <font color="blue"><font color="blue">additional</font> funds</font>, and if <font color="blue"><font color="blue">additional</font> capital</font> is not     available, we may have to limit, scale back or cease our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">existing cash</font> and other working capital (including the     <font color="blue">proceeds from</font> our <font color="blue">recent sale</font> of securities in <font color="blue">February </font>2006), together with     anticipated <font color="blue">proceeds from</font>  sales of our <font color="blue">products will</font> be sufficient to fund     our operating and capital <font color="blue"><font color="blue">requirement</font>s</font>, as currently planned through 2007</td>
    </tr>
    <tr>
      <td>Our currently planned operating and capital <font color="blue"><font color="blue">requirement</font>s</font> primarily include     the need for working capital to:       •     produce and <font color="blue">manufacture</font> our products;       •     support our sales and <font color="blue">marketing efforts</font> for our <font color="blue"><font color="blue">Embosphere Microsphere </font>    </font>products for UFE and other <font color="blue">indication</font>s, as well as our other products for     sale;       •     support our research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font>; and       •     fund our general and <font color="blue">administrative</font> costs and expenses</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">cash <font color="blue"><font color="blue">requirement</font>s</font> may vary materially from</font> those now planned     due to a number of factors, including, <font color="blue">without limitation</font>, the amount of     revenues we <font color="blue">generate from sales</font> of our products, in       17     ______________________________________________________________________       <font color="blue">particular from</font> the use of our <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>for UFE; changes in     our  UFE  <font color="blue">regulatory</font>  and marketing programs; anticipated research and     <font color="blue">development</font> efforts; cost and time involved in preclinical and clinical     testing; costs resulting from changes in the focus and direction of our     research and <font color="blue">development</font> programs; <font color="blue">competitive</font> advances that make it harder     for  us  to  market  and sell our products; the timing and cost of FDA     <font color="blue">regulatory</font> review; and the market’s <font color="blue">acceptance</font> of any <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>We also expect to <font color="blue">incur <font color="blue">additional</font> costs</font> related to <font color="blue">ongoing research</font> and     <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font>, preclinical studies, <font color="blue">clinical trials</font>, the expansion     of our <font color="blue">manufacturing</font>, laboratory and <font color="blue">administrative</font> functions, as well as     costs relating to <font color="blue">further market <font color="blue">development</font></font> and <font color="blue"><font color="blue">commercialization</font> efforts</font></td>
    </tr>
    <tr>
      <td>We may also need <font color="blue"><font color="blue">additional</font> funds</font> for <font color="blue">possible strategic <font color="blue"><font color="blue">acquisition</font>s</font></font> of     synergistic businesses, products and/or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are     not available, we may be required to delay, scale back or eliminate some of     our research, <font color="blue">development</font>, sales and marketing <font color="blue">initiatives</font>, which would have     a material adverse effect on our business, results of <font color="blue">operations</font> and ability     to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may need to raise <font color="blue"><font color="blue">additional</font> funds</font> to develop and <font color="blue">commercialize</font> our new     <font color="blue">products <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot fund</font> these <font color="blue"><font color="blue">new products</font> through cash</font>     generated from existing <font color="blue">operations</font> and <font color="blue">cannot raise</font> more funds, we could be     required  to  reduce  our capital <font color="blue">expenditures</font>, scale back our product     <font color="blue">development</font>,  reduce  our  workforce and license to <font color="blue">others products</font> or     <font color="blue">technologies</font>  that we <font color="blue">otherwise would seek</font> to <font color="blue">commercialize</font> ourselves</td>
    </tr>
    <tr>
      <td>Although we may seek <font color="blue">additional</font> funding through collaborative arrangements,     <font color="blue">borrowing money</font> or the sale of <font color="blue"><font color="blue">additional</font> equity securities</font>, we may not     receive <font color="blue"><font color="blue">additional</font> funding on reasonable terms</font>, or at all</td>
    </tr>
    <tr>
      <td>Any sales of     <font color="blue"><font color="blue">additional</font> shares</font> of our <font color="blue">capital stock</font> are likely to dilute our existing     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Further, if we issue <font color="blue"><font color="blue">additional</font> equity securities</font>, the <font color="blue">new equity securities</font>     may have rights, preferences or <font color="blue">privileges senior</font> to those of existing     holders  of  our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Alternatively, we <font color="blue">may borrow money from</font>     commercial lenders, possibly at high interest rates, which will increase the     risk of your <font color="blue">investment</font> in us</td>
    </tr>
    <tr>
      <td>If operating results <font color="blue">fluctuate <font color="blue"><font color="blue">significant</font>ly</font> from quarter</font> to quarter, then     our <font color="blue"><font color="blue">stock price may</font> decline</font></td>
    </tr>
    <tr>
      <td>Our operating results could <font color="blue">fluctuate <font color="blue"><font color="blue">significant</font>ly</font> from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">fluctuations</font> may</font> be due to a number of factors, including:       the timing and volume of <font color="blue">customer orders</font> for our products;       •     <font color="blue">procedure cancellations</font>;       •     <font color="blue">introduction</font> or <font color="blue">announcement</font> of <font color="blue"><font color="blue">competitive</font> products</font>;       •     <font color="blue">regulatory</font> approvals;       •     <font color="blue">product recalls</font>;       •     turnover in our <font color="blue">direct <font color="blue">sales force</font></font>;       •     timing and amount of expenses;       •     <font color="blue">reductions</font> in <font color="blue">orders by</font> our <font color="blue">distributors</font>;       •     <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">new marketing</font> and <font color="blue">sales program</font>;       •     changes in <font color="blue">management</font>;       •     <font color="blue">negative publicy</font>; and       •     <font color="blue">general economic <font color="blue">conditions</font></font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       Due to these <font color="blue">fluctuations</font>, our operating results in some quarters may not     meet the <font color="blue">expectations</font> of our investors</td>
    </tr>
    <tr>
      <td>In that case, our <font color="blue">stock price may</font>     decline</td>
    </tr>
    <tr>
      <td>In  addition,  a large portion of our expenses, including expenses for     facilities, equipment and personnel, are <font color="blue">relatively</font> fixed</td>
    </tr>
    <tr>
      <td>Accordingly, if     our <font color="blue">revenues decline</font> or do not grow as much as we anticipate, we might not     be able to improve our operating margins</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  achieve  anticipated  levels  of revenues could therefore     <font color="blue"><font color="blue">significant</font>ly</font> harm our operating results for a <font color="blue">particular fiscal period</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Industry, Business and Strategy       If  we  do not achieve <font color="blue"><font color="blue">widespread market</font> <font color="blue">acceptance</font></font> of our <font color="blue">microsphere</font>     products, our business <font color="blue">prospects will</font> be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">microsphere</font>s are <font color="blue">based on</font> new <font color="blue">technologies</font> and <font color="blue"><font color="blue">therapeutic</font> approaches</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we <font color="blue">began selling</font> our <font color="blue">microsphere</font> product in the first     half of 2000</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2002, we received FDA clearance to market our     Embosphere  Microspheres  in the <font color="blue"><font color="blue">United States</font> </font>for specific use in the     <font color="blue">embolization</font> of <font color="blue">uterine fibroids</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend upon increasing</font>     <font color="blue"><font color="blue">acceptance</font> by</font> the medical <font color="blue">community</font>, patients and third-party payers that     our <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>and other products are <font color="blue">medically <font color="blue">therapeutic</font></font> and     cost  <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">embolotherapy</font>  <font color="blue">techniques</font>  are  <font color="blue">administered by</font>     <font color="blue"><font color="blue"><font color="blue">interventional</font> radiologist</font>s</font></td>
    </tr>
    <tr>
      <td>To date we have not achieved <font color="blue">widespread market</font>     <font color="blue">acceptance</font>  of  our  <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>or other products</td>
    </tr>
    <tr>
      <td>In the     treatment of <font color="blue">uterine fibroids</font> using UFE, we believe that we have not yet     achieved widespread <font color="blue">acceptance</font> primarily because obstetrics and <font color="blue">gynecology</font>     <font color="blue">physicians may elect</font> to offer and provide other forms of treatment to their     patients with <font color="blue">uterine fibroids</font> that do not require a referral to another     <font color="blue">specialist</font>, such as an <font color="blue"><font color="blue">interventional</font> radiologist</font></td>
    </tr>
    <tr>
      <td>The majority of our     revenues  are  from  the  sale  of our EmboSphere Microsheres for UFE     Accordingly, our <font color="blue">future success will depend upon obstetrics</font> and <font color="blue">gynecology</font>     physicians referring patients to <font color="blue"><font color="blue"><font color="blue">interventional</font> radiologist</font>s</font> to receive     treatment using our <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>in lieu of, or in addition to,     receiving  other forms of treatment that the obstetrics and <font color="blue">gynecology</font>     physicians can <font color="blue">otherwise provide directly</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">publicity associated with</font> any <font color="blue">adverse medical effects attributed</font> to     <font color="blue">embolization</font> <font color="blue">treatments</font> <font color="blue">generally</font>, or our products <font color="blue">specifically</font>, may create     the <font color="blue">market <font color="blue">perception</font></font> that our products are unsafe</td>
    </tr>
    <tr>
      <td>For example, patients     commonly  experience  a day or two of post-procedure abdominal pain or     cramping</td>
    </tr>
    <tr>
      <td>Other infrequently occurring <font color="blue">complications may</font> include allergic     reactions, rashes, early onset of menopause, infertility and infection that     may, in some cases, require a <font color="blue">hysterectomy</font></td>
    </tr>
    <tr>
      <td>We are also aware that a small     number of the patient population, which we believe <font color="blue">constitutes <font color="blue">approximately</font></font>     2prca  of  those receiving the UFE <font color="blue">procedure using</font> EmboGold Microspheres,     reported a <font color="blue">delayed onset</font> of rash and/or pain</td>
    </tr>
    <tr>
      <td>If our <font color="blue">microsphere</font> products are not <font color="blue"><font color="blue">properly use</font>d</font> or if the market concludes     that our products are not safe or <font color="blue">effective</font>, our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue">microsphere</font>s are designed to <font color="blue">permanently occlude targeted <font color="blue">blood vessels</font></font></td>
    </tr>
    <tr>
      <td>There is some risk that some or all of the <font color="blue">microsphere</font>s used in a medical     <font color="blue">procedure may travel</font> in the <font color="blue">blood system</font> to sites other than the intended     <font color="blue">surgical site</font> and occlude, or block, other <font color="blue">blood vessels</font>, resulting in the     potential for <font color="blue"><font color="blue"><font color="blue">significant</font> adverse</font> <font color="blue">health effects on</font></font> the patient or, in a     worst case, even death</td>
    </tr>
    <tr>
      <td>Moreover, to use our <font color="blue">microsphere</font>s correctly for a     particular medical procedure, trained physicians must select and use the     proper size and quantity</td>
    </tr>
    <tr>
      <td>A physician’s selection and use of the wrong size     or quantity of our <font color="blue">microsphere</font>s could potentially have <font color="blue"><font color="blue">significant</font> adverse</font>     <font color="blue">health effects on</font> the patient, including death</td>
    </tr>
    <tr>
      <td>It is <font color="blue">necessary</font> for us to     educate  <font color="blue">physicians about</font> the selection and use of the proper size and     quantity of <font color="blue">microsphere</font>s in <font color="blue">patient therapy</font></td>
    </tr>
    <tr>
      <td>In addition, there is only     limited <font color="blue">data concerning</font> the long-term <font color="blue">health effects on</font> persons receiving     <font color="blue">embolotherapy</font> using our <font color="blue">microsphere</font>s</td>
    </tr>
    <tr>
      <td>For example, the effect of UFE on     <font color="blue">continued fertility</font> has       19     ______________________________________________________________________       not <font color="blue">yet been <font color="blue">specifically</font> studied</font>, and our FDA clearance for Embosphere     Microspheres currently does not include women who desire <font color="blue">future pregnancy</font></td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue"><font color="blue">successfully</font> educate physicians</font> to <font color="blue">properly use</font> our     product, or if the market determines or concludes that any of our products     are not safe or <font color="blue">effective</font> for any reason, we may be exposed to product     <font color="blue">liability</font> claims, <font color="blue">product recalls</font>, fines or other penalties or <font color="blue">enforcement</font>     actions  by  <font color="blue">regulatory</font> agencies and <font color="blue">associated <font color="blue">adverse publicity</font></font></td>
    </tr>
    <tr>
      <td>For     example,  in <font color="blue">September </font>2005, we were named as a <font color="blue">defendant</font> in a product     <font color="blue">liability</font> lawsuit in which the <font color="blue">defendant</font>, a minor child, claims that he was     rendered  blind  in <font color="blue">both eyes as</font> a result of the use of our Embosphere     Microsphere <font color="blue">product during</font> a nasal angiofibroma <font color="blue">embolization</font></td>
    </tr>
    <tr>
      <td>See “We may be     exposed to product <font color="blue">liability</font> claims, and if we are unable to obtain or     maintain adequate product <font color="blue">liability</font> insurance, then we may have to pay     <font color="blue"><font color="blue">significant</font> monetary damages</font> in a successful product <font color="blue">liability</font> claim against     us</td>
    </tr>
    <tr>
      <td>”  While we have product <font color="blue">liability</font> insurance, we may not be able to     maintain <font color="blue">such insurance at</font> favorable rates, or at all, and any successful     judgments  against  <font color="blue">us could exceed</font> our coverage</td>
    </tr>
    <tr>
      <td>In addition, we have     provided to our customers a <font color="blue"><font color="blue">satisfaction</font> guarantee</font> that requires us to     accept the return of any inventory and credit the <font color="blue">entire amount</font> of the     original order if a <font color="blue">properly trained customer</font> is not <font color="blue">satisfied with</font> the     performance of our <font color="blue">microsphere</font>s or our <font color="blue">delivery system products</font></td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">adverse publicity</font> or are subject to product <font color="blue">liability</font>     claims, <font color="blue">excessive guarantee</font> claims, recalls, fines and the like, we will be     unable to achieve <font color="blue"><font color="blue">widespread market</font> <font color="blue">acceptance</font></font> of our <font color="blue">microsphere</font> products     and achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>For example, in March 2006, we announced that we     had instituted a <font color="blue">voluntary recall</font> of our HepaSphere Microspheres in Europe     and Japan to correct a packaging defect that we identified while conducting     aging  studies  routinely  performed  on all of our product packaging</td>
    </tr>
    <tr>
      <td>HepaSphere Microspheres are contained in a <font color="blue">prefilled vial</font> that is in turn     packaged inside a <font color="blue">paper pouch</font></td>
    </tr>
    <tr>
      <td>We determined that a defect in the paper     pouch  <font color="blue">may compromise</font> the sterility of the outside of the vial</td>
    </tr>
    <tr>
      <td>If the     sterility of the outside of the vial is not maintained, there is the risk     that a physician’s hands can <font color="blue">become contaminated</font> when handling the vial</td>
    </tr>
    <tr>
      <td>Although we are not aware of any <font color="blue">adverse events</font> resulting from the defects     in the <font color="blue">paper packaging</font>, our <font color="blue">voluntary recall</font> of this product could result in     <font color="blue"><font color="blue">reputational</font> harm</font> or a <font color="blue">perception</font> that the product is not safe, either of     <font color="blue">which could</font> <font color="blue">adversely</font> affect market <font color="blue">acceptance</font> of our <font color="blue">microsphere</font> products</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue"><font color="blue">successfully</font> market</font> and promote our <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>for     use in uterine fibroid <font color="blue">embolization</font>, our product revenues will not increase</td>
    </tr>
    <tr>
      <td>In the first quarter of 2003, we launched our ask4UFE campaign to increase     awareness among patients, referring physicians, <font color="blue"><font color="blue"><font color="blue">interventional</font> radiologist</font>s</font>     and third-party payers of UFE as an <font color="blue"><font color="blue">alternative</font> treatment</font> for fibroids</td>
    </tr>
    <tr>
      <td>We     believe the majority of our revenues in the <font color="blue"><font color="blue">United States</font> </font>for the two years     ended  <font color="blue">December </font>31,  2005  were  derived  from  the sale of Embosphere     Microspheres for use <font color="blue">in UFE Although </font>we believe that <font color="blue"><font color="blue">EmboGold Microspheres </font>    </font>accounted for a <font color="blue">significant</font> portion of revenue, we currently do not intend     to seek 510(k) clearance for use of <font color="blue">EmboGold Microspheres </font>in UFE Because we     do not intend to seek 510(k) clearance of EmboGold Microspheres, we believe     that our <font color="blue">future product revenues</font> are <font color="blue"><font color="blue">substantially</font> dependent on</font> our ability     to achieve widespread <font color="blue">acceptance</font> of the use of <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>for     the  treatment  of  UFE, and if we do not achieve increased widespread     <font color="blue">acceptance</font>,  our  product  revenues, <font color="blue">profitability</font> and success will be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We are continuing to market <font color="blue">EmboGold Microspheres </font>for     use  in  <font color="blue">hypervascularized</font>  tumors  (other  than <font color="blue">uterine fibroids</font>) and     <font color="blue">arteriovenous</font> <font color="blue">malformations</font></td>
    </tr>
    <tr>
      <td>If we cease to market <font color="blue">EmboGold Microspheres </font>for     any  reason, we <font color="blue">could incur</font> substantial costs to write off and replace     existing <font color="blue">inventories</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had EmboGold inventory     with  a  carrying value of dlra228cmam000, including in-process inventory of     dlra144cmam000 and finished goods syringes of dlra84cmam000</td>
    </tr>
    <tr>
      <td>We currently believe no     provision  for  the  write-off or <font color="blue">replacement</font> of <font color="blue"><font color="blue">EmboGold Microspheres </font>    </font>inventory is required in the <font color="blue">accompanying financial statements</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       If we do not maintain our <font color="blue"><font color="blue">relationships</font> with</font> the <font color="blue">healthcare <font color="blue">community</font></font>, our     <font color="blue">growth will</font> be limited and our business could be harmed</td>
    </tr>
    <tr>
      <td>If <font color="blue">gynecologists</font>,     <font color="blue">obstetricians</font>, <font color="blue"><font color="blue"><font color="blue">interventional</font> radiologist</font>s</font> and other <font color="blue">healthcare providers</font> do     not recommend and endorse our products, our sales may decline or we may be     unable to increase our sales and profits</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">relationships</font>  with  <font color="blue">gynecologists</font>, <font color="blue">obstetricians</font>, <font color="blue">interventional</font>     <font color="blue">radiologists</font> and other <font color="blue">healthcare providers</font> are critical to our continued     growth</td>
    </tr>
    <tr>
      <td>We believe that these <font color="blue">relationships</font> are <font color="blue">based on</font> the quality of our     products, our long-standing <font color="blue">commitment</font> to <font color="blue">embolotherapy</font> <font color="blue">treatments</font>, our     <font color="blue">marketing efforts</font> and our <font color="blue">presence at medical society</font> and <font color="blue">trade association</font>     meetings</td>
    </tr>
    <tr>
      <td>Any actual or perceived <font color="blue">diminution</font> in our reputation or the     quality of our products, or our failure or <font color="blue">inability</font> to maintain these other     <font color="blue">efforts could damage</font> our current <font color="blue">relationships</font>, or <font color="blue">prevent us from forming</font>     new <font color="blue">relationships</font>, with <font color="blue">healthcare professionals</font> and cause our growth to be     limited and our business to be harmed</td>
    </tr>
    <tr>
      <td>In  order  for  us to sell our products, <font color="blue">healthcare professionals</font> must     recommend and <font color="blue">endorse them</font></td>
    </tr>
    <tr>
      <td>We may not obtain the <font color="blue">necessary</font> <font color="blue">recommendations</font>     or <font color="blue"><font color="blue">endorsements</font> from</font> this <font color="blue">community</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products depends on     educating the medical <font color="blue">community</font> as to the <font color="blue">distinctive characteristics</font>,     perceived benefits, safety, clinical efficacy and cost-<font color="blue"><font color="blue">effective</font>ness</font> of our     <font color="blue">products compared</font> to <font color="blue">traditional methods</font> of treatment and the products of     our <font color="blue">competitors</font>, and <font color="blue">on training <font color="blue">healthcare professionals</font></font> in the proper     <font color="blue">application</font> of our products</td>
    </tr>
    <tr>
      <td>If we are not successful in obtaining the     <font color="blue">recommendations</font>   or  <font color="blue">endorsements</font>  of  <font color="blue">gynecologists</font>,  <font color="blue">obstetricians</font>,     <font color="blue">interventional</font>  <font color="blue">radiologists</font> and other <font color="blue">healthcare professionals</font> for our     products, our sales may decline or we may be unable to increase our sales     and profits</td>
    </tr>
    <tr>
      <td>If we experience delays, <font color="blue"><font color="blue">difficult</font>ies</font> or <font color="blue">unanticipated costs</font> in <font color="blue">establishing</font>     the sales, <font color="blue">distribution</font> and marketing <font color="blue">capabilities</font> <font color="blue">necessary</font> to <font color="blue">successfully</font>     <font color="blue">commercialize</font>  our  products,  we will have <font color="blue"><font color="blue">difficult</font>y</font> maintaining and     increasing our sales</td>
    </tr>
    <tr>
      <td>We are continuing to develop sales, <font color="blue">distribution</font> and marketing <font color="blue">capabilities</font>     in the <font color="blue">United States</font>, the <font color="blue">European Union</font>, Asia and in South America</td>
    </tr>
    <tr>
      <td>In     2003,  we  began a <font color="blue">marketing strategy</font> to promote UFE awareness and the     benefits of our product for the treatment of <font color="blue">uterine fibroids</font></td>
    </tr>
    <tr>
      <td>It will be     expensive and time-consuming for us to develop a <font color="blue">global marketing</font> and sales     force</td>
    </tr>
    <tr>
      <td>Moreover,  we  may choose, or find it <font color="blue">necessary</font>, to <font color="blue">enter into</font>     <font color="blue">strategic collaborations</font> to sell, market and distribute our products</td>
    </tr>
    <tr>
      <td>We     currently have a <font color="blue">sales force</font> of 18 persons located principally in the United     States</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for skilled <font color="blue">salespersons</font> in the medical device industry     is intense, and we may not be able to <font color="blue">provide adequate incentive</font> to maintain     our  <font color="blue">sales force</font> or to <font color="blue">attract new sales personnel</font> or to establish and     maintain favorable <font color="blue">distribution</font> and <font color="blue">marketing collaborations with</font> other     companies to promote our products</td>
    </tr>
    <tr>
      <td>We have only limited sales and marketing     experience both in the <font color="blue"><font color="blue">United States</font> </font>and <font color="blue"><font color="blue">international</font>ly</font> and may not be     successful in developing and <font color="blue">implementing</font> our strategy</td>
    </tr>
    <tr>
      <td>Among other things,     we need to:       ·        provide or assure that <font color="blue">distributors</font> provide the technical and     <font color="blue">education</font>al support customers need to use our <font color="blue">products <font color="blue">successfully</font></font>;       ·       establish and implement successful sales and marketing and <font color="blue">education</font>     programs that encourage our customers to purchase our products;       ·       manage <font color="blue">geographically</font> dispersed <font color="blue">operations</font>; and       ·       modify our products and marketing and <font color="blue">sales program</font>s for foreign     markets</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">distribution</font> <font color="blue">agreements</font> with <font color="blue">approximately</font> 45 third-party     <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">third party with whom</font> we have established a marketing and     <font color="blue">distribution</font> relationship may not <font color="blue">devote sufficient</font> time to the marketing     and sales of our products, thereby exposing us to <font color="blue">potential expenses</font> in     terminating such <font color="blue">distribution</font> <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>For example, our subsidiary,     <font color="blue">BioSphere </font>Medical SA, or BSMA, ended its <font color="blue">distribution</font> <font color="blue">agreement with</font>     <font color="blue">Terumo NV </font>in 2002 in part because of Terumo’s failure to achieve sales     <font color="blue">forecasts agreed upon by</font> the parties</td>
    </tr>
    <tr>
      <td>As a result of subsequent <font color="blue">litigation</font>     in <font color="blue">December </font>2004, BSMA was       21     ______________________________________________________________________       required to pay Terumo <font color="blue">approximately</font> dlra784cmam000 in damages arising from such     <font color="blue">termination</font>  and <font color="blue">incurred <font color="blue">additional</font> legal</font> and <font color="blue">administrative</font> expenses     incident  to  the  legal  proceeding</td>
    </tr>
    <tr>
      <td>We  and  any of our third-party     <font color="blue"><font color="blue">collaborators</font> must also market</font> our products in <font color="blue">compliance with federal</font>,     state  and  local  laws  relating  to  the providing of <font color="blue">incentives</font> and     <font color="blue">inducements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Violation </font>of these laws can result in substantial penalties</td>
    </tr>
    <tr>
      <td>If     we are unable to <font color="blue">successfully</font> motivate and expand our marketing and sales     force and further develop our sales and marketing <font color="blue">capabilities</font>, or if our     <font color="blue">distributors</font>  fail  to  promote  our products, we will have <font color="blue"><font color="blue">difficult</font>y</font>     maintaining and increasing our sales</td>
    </tr>
    <tr>
      <td>We  may  be  required  to  expend  <font color="blue">significant</font> resources for research,     <font color="blue">development</font>,  testing  and  <font color="blue">regulatory</font>  approval of our <font color="blue">products under</font>     <font color="blue">development</font>, and these <font color="blue">products may</font> not be developed <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We are developing and <font color="blue">commercializing products</font> for medical <font color="blue">application</font>s     using <font color="blue">embolotherapy</font> <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td>Most of our next-generation <font color="blue">embolotherapy</font>     product <font color="blue">candidates</font>, including MR-<font color="blue">Embosphere Microspheres</font>, EmboCath Plus     Infusion Microcatheter and Sequitor Steerable Guidewire, are still in the     <font color="blue">early stages</font> of research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> not provide     greater  benefits  <font color="blue">than current <font color="blue">treatments</font></font> or products, or <font color="blue">alternative</font>     <font color="blue">treatments</font>  or  products  under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>All of our <font color="blue">products under</font>     <font color="blue">development</font> will require <font color="blue">significant</font> <font color="blue">additional</font> research, <font color="blue">development</font>,     <font color="blue">engineering</font>, preclinical and/or clinical testing, <font color="blue">regulatory</font> approval and a     <font color="blue">commitment</font>   of   <font color="blue">significant</font>  <font color="blue">additional</font>  resources  prior  to  their     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our potential <font color="blue">products may</font> not:       •     be developed <font color="blue">successfully</font>;       •     be proven safe and <font color="blue">effective</font> in <font color="blue">clinical trials</font>;       •     offer <font color="blue">therapeutic</font> or other improvements over current <font color="blue">treatments</font> and     products;       •     meet applicable <font color="blue">regulatory</font> standards or receive <font color="blue">regulatory</font> approvals;       •     be capable of production in <font color="blue">commercial quantities at</font> acceptable costs;     or       •     be <font color="blue"><font color="blue">successfully</font> market</font>ed</td>
    </tr>
    <tr>
      <td>If  we  do  not develop and <font color="blue">introduce <font color="blue">new products</font></font>, we may not achieve     <font color="blue">additional</font> revenue <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We  derived  <font color="blue">approximately</font>  13prca  of  our revenues for the period ended     <font color="blue">December </font>31, 2005 from the sale of nonstrategic <font color="blue">medical products</font> that we     expect <font color="blue">will constitute</font> a less <font color="blue">significant</font> portion of our <font color="blue">revenues on</font> an     <font color="blue">ongoing basis</font></td>
    </tr>
    <tr>
      <td>These nonstrategic <font color="blue">medical products</font> include <font color="blue">barium delivery</font>     <font color="blue">kits sold by us</font> in the <font color="blue">European Union</font>, as well as other <font color="blue">ancillary devices</font>     for hospital and <font color="blue">physician use</font></td>
    </tr>
    <tr>
      <td>In addition, we estimate that a <font color="blue">significant</font>     portion of our revenues for the years ended <font color="blue">December </font>31, 2005 and 2004 were     <font color="blue">derived from</font> the sale of <font color="blue">EmboGold Microspheres </font>for UFE, an <font color="blue">indication</font> for     which we do not have, and do not presently intend to seek, clearance from     the FDA to market</td>
    </tr>
    <tr>
      <td>We made the decision not to seek FDA clearance for our     <font color="blue">EmboGold Microsphere </font>product because of reports that a small number of     patients treated with UFE using EmboGold Microspheres, which we believe     constitute <font color="blue">approximately</font> 2prca of the total number of patients receiving the     procedure, reported a <font color="blue">delayed onset</font> of rash and/or pain</td>
    </tr>
    <tr>
      <td>Accordingly, we     need  to  develop and introduce new <font color="blue">application</font>s for our <font color="blue">embolotherapy</font>     <font color="blue">technology</font> and <font color="blue">pursue <font color="blue">opportunities</font></font> for <font color="blue">microsphere</font> <font color="blue">technology</font> in other     medical  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Any such new <font color="blue">application</font> for our <font color="blue">embolotherapy</font>     <font color="blue">technology</font> or <font color="blue">microsphere</font> <font color="blue">technology</font> will be subject to a number of risks     inherent  in the <font color="blue">development</font> and <font color="blue">commercialization</font> of a medical device     product, including <font color="blue">uncertainties <font color="blue">with respect</font></font> to the <font color="blue">successful completion</font>     of <font color="blue">clinical trials</font>, our ability to achieve and maintain, and our <font color="blue">willingness</font>     to seek, required <font color="blue">regulatory</font> approvals and our ability to <font color="blue">successfully</font>     <font color="blue">commercialize</font>, market and sell these new <font color="blue">application</font>s assuming FDA approval     is achieved</td>
    </tr>
    <tr>
      <td>If, as a result of these or other risks, we are not successful     in developing new <font color="blue">application</font>s and products, we will not achieve new revenue     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       We may be exposed to product <font color="blue">liability</font> claims, and if we are unable to     obtain or maintain adequate product <font color="blue">liability</font> insurance, then we may have to     pay <font color="blue"><font color="blue">significant</font> monetary damages</font> in a successful product <font color="blue">liability</font> claim     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and sale of <font color="blue"><font color="blue">medical devices</font> entails</font> an <font color="blue">inherent risk</font> of     product <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>For example, if we are not able to <font color="blue">successfully</font> educate     physicians to <font color="blue">properly use</font> our products, if patients experience adverse side     effects in procedures in which our products are used, or if the market     determines or concludes that any of our products are not safe or <font color="blue">effective</font>     for any reason, we may be exposed to product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Although we     maintain insurance, including product <font color="blue">liability</font> insurance, we <font color="blue">cannot provide</font>     assurance that any claim that may be brought <font color="blue">against us</font> will not result in     <font color="blue">court judgments</font> or <font color="blue">settlements</font> in amounts that are in excess of the limits     of  our  insurance  coverage</td>
    </tr>
    <tr>
      <td>Our <font color="blue">insurance policies also</font> have various     <font color="blue">exclusions</font>, and we may be subject to a product <font color="blue">liability</font> claim for which we     have no coverage</td>
    </tr>
    <tr>
      <td>We will have to pay any <font color="blue">amounts awarded by</font> a court or     negotiated in a settlement that exceed our <font color="blue">coverage limitations</font> or that are     not <font color="blue">covered by</font> our insurance</td>
    </tr>
    <tr>
      <td>In August 2005, we were named as a <font color="blue">defendant</font> in a <font color="blue">lawsuit commenced</font> in the     Circuit Court, Twenty-Second Judicial Circuit, St</td>
    </tr>
    <tr>
      <td>Louis, Missouri, which we     refer to as the <font color="blue">Pingel Claim</font></td>
    </tr>
    <tr>
      <td>The lawsuit alleges, among other things, that     a <font color="blue">patient suffered permanent bilateral blindness as</font> a result of the use of     our <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>in a juvenile nasal angiofibroma <font color="blue">embolization</font></td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font><font color="blue">seek compensatory</font> and <font color="blue">punitive damages</font></td>
    </tr>
    <tr>
      <td>Although we currently     maintain product <font color="blue">liability</font> insurance coverage for our products, including     the <font color="blue">Embosphere Microsphere </font>product that is the subject of the Pingel claim,     our <font color="blue">existing insurance</font> and any <font color="blue">additional</font> insurance we may subsequently     obtain may not <font color="blue">provide us with adequate coverage against</font> all potential     claims</td>
    </tr>
    <tr>
      <td>For example, although our product <font color="blue">liability</font> insurer has agreed to     <font color="blue">vigorously defend us with</font> regards to all of the counts set forth <font color="blue">against us</font>     in the <font color="blue">Pingel Claim</font>, the insurer has advised us in writing that any verdict     <font color="blue">against us</font> for <font color="blue">punitive damages</font> is <font color="blue">specifically</font> excluded from coverage</td>
    </tr>
    <tr>
      <td>The     insurer has <font color="blue">also advised us</font> that it does not waive any other defenses to     coverage that may apply</td>
    </tr>
    <tr>
      <td>Any product <font color="blue">liability</font> claim brought <font color="blue">against us</font>, with or without merit, could     result in the increase of our product <font color="blue">liability</font> insurance rates or the     <font color="blue">inability</font> to secure <font color="blue">additional</font> insurance coverage in the future</td>
    </tr>
    <tr>
      <td>A product     <font color="blue">liability</font>  claim, <font color="blue">whether meritorious</font> or not, could be time consuming,     <font color="blue">distracting</font> and expensive to defend, could be harmful to our reputation,     could result in a diversion of <font color="blue">management</font> and <font color="blue">financial <font color="blue">resources away from</font></font>     our primary business and could result in <font color="blue">product recalls</font></td>
    </tr>
    <tr>
      <td>We have instituted a <font color="blue">voluntary recall</font> of our HepaSphere Microspheres product     in  the <font color="blue"><font color="blue">European Union</font> </font>and Japan, which may result in <font color="blue">decreased market</font>     <font color="blue">acceptance</font> of this product and <font color="blue"><font color="blue">reputational</font> harm</font>, as well as hindering our     ability to <font color="blue">generate revenue from sales</font> of the product</td>
    </tr>
    <tr>
      <td>On March 13, 2006, we announced that we have instituted a <font color="blue">voluntary recall</font>     of our HepaSphere Microspheres in Europe and Japan to correct a packaging     defect that we identified while conducting aging studies routinely performed     on  all of our product packaging</td>
    </tr>
    <tr>
      <td>We  also  have had limited sales of HepaSphere     Microspheres  in  Japan <font color="blue">under private import <font color="blue">restrictions</font></font></td>
    </tr>
    <tr>
      <td>HepaSphere     Microspheres are contained in a <font color="blue">prefilled vial</font> that is in turn packaged     inside a <font color="blue">paper pouch</font></td>
    </tr>
    <tr>
      <td>We determined that a defect in the <font color="blue">paper pouch</font> may     compromise the sterility of the outside of the vial</td>
    </tr>
    <tr>
      <td>If the sterility of the     outside of the vial is not maintained, there is the risk that a physician’s     hands can <font color="blue">become contaminated</font> when handling the vial</td>
    </tr>
    <tr>
      <td>Although we are not     aware  of  any  <font color="blue">adverse events</font> resulting from the defects in the paper     packaging, our <font color="blue">voluntary recall</font> of this product could result in <font color="blue">reputational</font>     harm or a <font color="blue">perception</font> that the product is not safe, either of <font color="blue">which could</font>     <font color="blue">adversely</font> affect market <font color="blue">acceptance</font> of our <font color="blue">microsphere</font> products and result in     <font color="blue">decreased sales</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may encounter unanticipated</font>       23     ______________________________________________________________________       delays and expenses relating to correcting the packaging defect, <font color="blue">which could</font>     <font color="blue">adversely</font> affect our operating results</td>
    </tr>
    <tr>
      <td>If we are not able to compete <font color="blue">effective</font>ly, we may experience decreased     demand for our products, which may result in price <font color="blue">reductions</font></td>
    </tr>
    <tr>
      <td>We have many <font color="blue">competitors</font> in the <font color="blue"><font color="blue">United States</font> </font>and abroad, including medical     device,  bio<font color="blue">technology</font>  and  other  <font color="blue">alternative</font> <font color="blue">therapeutic</font> companies,     <font color="blue">universities</font> and other private and <font color="blue">public research institutions</font></td>
    </tr>
    <tr>
      <td>We have     experienced increased competition since receiving FDA approval for use of     our <font color="blue"><font color="blue">Embosphere Microspheres</font> </font>for UFE Our <font color="blue">success depends upon</font> our ability to     develop and maintain a <font color="blue"><font color="blue">competitive</font> position</font> in both the <font color="blue">embolotherapy</font> and     related <font color="blue">delivery systems markets</font></td>
    </tr>
    <tr>
      <td>Our key <font color="blue">competitors</font> in both the fields of     <font color="blue">embolotherapy</font>  and  the <font color="blue">delivery systems used</font> in the UFE procedure are     Angiodynamics  Incorporated,  Biocompatibles, Ltd,  Boston Scientific     Corporation, Cook Incorporated, Cordis Corporation, a Johnson and Johnson     Company, Pfizer, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Terumo Corporation</font></td>
    </tr>
    <tr>
      <td>These and many of our other     <font color="blue">competitors</font> have greater <font color="blue">capabilities</font>, experience and financial resources     than we do</td>
    </tr>
    <tr>
      <td>As a result, they may develop products quicker or at less cost,     that <font color="blue">compete with</font> our <font color="blue">microsphere</font> products and related delivery systems</td>
    </tr>
    <tr>
      <td>In     addition, we may experience <font color="blue">decreased demand</font> for our products if these or     other <font color="blue">competitors</font> announce that they have begun to develop products that     <font color="blue">compete with</font> our products</td>
    </tr>
    <tr>
      <td>For example, in 2004, some of our <font color="blue">competitors</font>     <font color="blue">provided free</font> or reduced-price samples of <font color="blue">competing forms</font> of <font color="blue">microsphere</font>s     for  the  treatment  of  medical  procedures  for which our Embosphere     Microspheres are indicated</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of these free or reduced-price     samples has had, and <font color="blue">may continue</font> to have, a material adverse effect on our     product revenues, primarily due to a loss of market share for the sale of     our products</td>
    </tr>
    <tr>
      <td>Currently, the primary <font color="blue">products with</font> which our <font color="blue">microsphere</font>s     compete for some of our <font color="blue">application</font>s are spherical PVA, sold by Boston     Scientific, Terumo and Biocompatibles, and gel foam, sold by Pfizer, and     non-spherical PVA, sold by Angiodynamics, Boston Scientific and Cook</td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue">competitors</font> may develop <font color="blue">technologies</font> that render our products     obsolete or <font color="blue">otherwise non<font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>We  may not be able to improve our products or develop <font color="blue">new products</font> or     <font color="blue">technologies</font> quickly enough to maintain a <font color="blue"><font color="blue">competitive</font> position</font> in our market     and continue to <font color="blue">commercially</font> develop our business</td>
    </tr>
    <tr>
      <td>Moreover, we may not be     able to compete <font color="blue">effective</font>ly, and <font color="blue"><font color="blue">competitive</font> pressures may</font> result in less     demand for our products and impair our ability to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>In the treatment of symptomatic <font color="blue">uterine fibroids</font>, we also <font color="blue">compete with</font>     obstetrics and <font color="blue">gynecology</font> physicians who elect to offer and provide other     forms of treatment to their patients with <font color="blue">uterine fibroids</font> that do not     require referral to another <font color="blue">specialist</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain, or in some instances obtain, an <font color="blue">adequate level</font> of     <font color="blue">reimbursement</font>  for our products by third-party payers, there may be no     <font color="blue">commercially</font> viable markets for our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> and levels of <font color="blue">reimbursement</font> by governmental and other     third-party payers affects the market for any medical device</td>
    </tr>
    <tr>
      <td>We may not be     able to sell our <font color="blue">products profitably</font> if <font color="blue">reimbursement</font> is unavailable or     limited in scope or amount</td>
    </tr>
    <tr>
      <td>Some <font color="blue">insurance companies</font> do not <font color="blue">fully reimburse</font>     for <font color="blue">embolization</font> procedures</td>
    </tr>
    <tr>
      <td>These third-party payers attempt to contain or     reduce the costs of <font color="blue">healthcare by <font color="blue">challenging</font></font> the prices that <font color="blue">companies such</font>     <font color="blue">as ours charge</font> for <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>In some foreign countries, particularly     the countries of the <font color="blue"><font color="blue">European Union</font> </font>where our <font color="blue">microsphere</font> products are     <font color="blue">currently marketed</font> and sold, the pricing of <font color="blue">medical devices</font> is subject to     <font color="blue">governmental control</font>, and the <font color="blue">prices charged</font> for our products have in some     <font color="blue">instances been reduced as</font> a result of these controls</td>
    </tr>
    <tr>
      <td><font color="blue">Initiatives  </font>to  limit the growth of healthcare costs, including price     regulation, are underway in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">major healthcare</font>     markets</td>
    </tr>
    <tr>
      <td>For example, these proposals include <font color="blue">prescription drug benefit</font>     <font color="blue">legislation recently enacted</font> in the <font color="blue">United States</font>, and healthcare reform     <font color="blue">initiatives</font> proposed in certain state and local <font color="blue">jurisdictions</font> and other     countries</td>
    </tr>
    <tr>
      <td>While these <font color="blue">initiatives</font> have in many cases related       24     ______________________________________________________________________       to  pharmaceutical pricing, implementation of more <font color="blue">sweeping healthcare</font>     reforms in <font color="blue">significant</font> markets may limit the price of, or the <font color="blue">level at which</font>     <font color="blue">reimbursement</font> is provided for, our products and <font color="blue">may influence</font> a physician’s     selection of <font color="blue">products used</font> to <font color="blue">treat patients</font></td>
    </tr>
    <tr>
      <td>If we do not retain our senior <font color="blue">management</font>, other <font color="blue">key employees</font>, scientific     <font color="blue">collaborators</font> and advisors, we may not be able to <font color="blue">successfully</font> implement our     business strategy</td>
    </tr>
    <tr>
      <td>The  loss of key members of our <font color="blue">management</font> team <font color="blue">could harm</font> us</td>
    </tr>
    <tr>
      <td>We have     recently  experienced <font color="blue">significant</font> changes in <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In late 2004,     Richard Faleschini, our president and <font color="blue">chief executive officer</font>, Gary M     Saxton, our <font color="blue">executive vice president</font> and chief operating officer, and Martin     Joyce, our <font color="blue">executive vice president</font> and chief financial officer, joined our     company</td>
    </tr>
    <tr>
      <td>Our former president and <font color="blue">chief executive officer</font> only served as our     president and <font color="blue">chief executive officer</font> for <font color="blue">approximately</font> 27 months; our     former  vice  president of US sales and <font color="blue">marketing served as</font> our vice     president of US sales for <font color="blue">approximately</font> 34 months; and our <font color="blue">former vice</font>     president of research and <font color="blue">development</font> served for <font color="blue">approximately</font> five years</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue"><font color="blue">substantially</font> dependent on</font> our ability  to retain members of     our senior <font color="blue">management</font> and other <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>We do not carry <font color="blue">key man life</font>     <font color="blue">insurance on</font> any of our <font color="blue">executive officers</font> or other personnel</td>
    </tr>
    <tr>
      <td>If we make any <font color="blue"><font color="blue">acquisition</font>s</font>, we will incur a variety of costs and may never     <font color="blue">successfully</font> integrate the acquired business into ours</td>
    </tr>
    <tr>
      <td>We <font color="blue">may attempt</font> to acquire businesses, <font color="blue">technologies</font>, services or products     that we believe are a <font color="blue">strategic complement</font> to our business model</td>
    </tr>
    <tr>
      <td>We may     encounter operating <font color="blue"><font color="blue">difficult</font>ies</font> and <font color="blue">expenditures</font> relating to <font color="blue">integrating</font> an     acquired business, <font color="blue">technology</font>, service or product</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">acquisition</font>s</font> may     also  absorb  <font color="blue">significant</font> <font color="blue">management</font> attention that <font color="blue">would otherwise</font> be     available for ongoing <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>Moreover, we may never     realize  the anticipated benefits of any <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>We may also make     <font color="blue">dilutive issuances</font> of equity securities, incur debt or experience a decrease     in the <font color="blue">cash available</font> for our <font color="blue">operations</font>, or <font color="blue">incur contingent liabilities</font> in     <font color="blue">connection with</font> any future <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>Because key <font color="blue">stockholders</font> <font color="blue">beneficially</font> own a <font color="blue">significant</font> amount of our common     stock, they may be able to <font color="blue">exert control over us</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>1, 2006, Sepracor Inc, or Sepracor, and funds <font color="blue">affiliated</font> with     Cerberus  Capital  Management,  LP,  or Cerberus, <font color="blue">beneficially</font> owned     <font color="blue">approximately</font> 23prca and 14prca of our outstanding <font color="blue">common stock</font>, respectively,     including shares of <font color="blue">common stock</font> issuable upon the exercise of warrants and     series A <font color="blue">preferred stock</font> held by these <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Moreover, two of our     <font color="blue">directors</font> are <font color="blue">executive officers</font> of Sepracor and we have granted board     <font color="blue">observation</font> rights to Cerberus</td>
    </tr>
    <tr>
      <td>Accordingly, Sepracor and Cerberus may have     <font color="blue">significant</font> influence over corporate actions requiring <font color="blue">stockholder approval</font>,     such as the election of <font color="blue">directors</font>, amendment of our <font color="blue">charter documents</font> and     the approval of merger or <font color="blue">significant</font> asset sale <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>In addition,     the shares of our series A <font color="blue">preferred stock</font> held by Sepracor and Cerberus     <font color="blue">entitled them</font> to <font color="blue">certain voting rights</font> in <font color="blue">accordance with</font> the terms and     <font color="blue">conditions</font> of the series A <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>Specifically, we will need the     consent of holders of at least 50prca of the series A <font color="blue">preferred stock</font> initially     purchased  by Sepracor and Cerberus to undertake certain key corporate     actions, including the following:       •     amending our charter or bylaws in a manner that <font color="blue">adversely</font> affects the     holders of series A <font color="blue">preferred stock</font>;       •     <font color="blue">authorizing</font> or issuing any <font color="blue">equity security</font> that is senior to or pari     <font color="blue">passu with</font> the series A <font color="blue">preferred stock</font>; and       •     declaring or paying any <font color="blue">dividends on</font>, or redeeming or <font color="blue">repurchasing</font> any     shares of, our <font color="blue">capital stock</font>, subject to <font color="blue">customary exceptions</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       The <font color="blue">ownership concentration</font> of Sepracor and Cerberus could cause the market     price of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>In addition, conflicts of interest     between these key <font color="blue">stockholders</font> and us may arise, including <font color="blue">with respect</font> to     <font color="blue">competitive</font>  business <font color="blue">activities</font> and control of our <font color="blue">management</font> and our     affairs</td>
    </tr>
    <tr>
      <td>The holders of shares of our series A <font color="blue">preferred stock</font> have rights that could     <font color="blue">adversely</font> affect an <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The holders of our series A <font color="blue">preferred stock</font> have the right to an <font color="blue">adjustment</font>     in  the  <font color="blue">conversion</font>  rate  of the series A <font color="blue">preferred stock</font> if we issue     <font color="blue">securities at</font> a price below the <font color="blue">purchase price paid by</font> these holders</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions could <font color="blue">substantially</font> dilute <font color="blue">stockholders</font>’ interest in <font color="blue">BioSphere </font>in     the  event  of  future financing <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>The holders of series A     <font color="blue">preferred stock</font> also have the right to receive a 6prca dividend per annum     which, at our election, may be paid in cash or <font color="blue"><font color="blue">additional</font> shares</font> of series A     preferred  stock</td>
    </tr>
    <tr>
      <td>To date all <font color="blue">such dividend payments</font> have been made in     <font color="blue"><font color="blue">additional</font> shares</font> of series A <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such dividends continue</font> to     be paid in stock, this dividend could also further dilute <font color="blue">stockholders</font>’     <font color="blue">ownership interest</font></td>
    </tr>
    <tr>
      <td>In addition, the holders of our series A <font color="blue">preferred stock</font>     have the right to <font color="blue">participate</font> in future capital raising <font color="blue">transactions</font> by     BioSphere</td>
    </tr>
    <tr>
      <td>The existence of this right may reduce our ability to establish     terms <font color="blue">with respect</font> to, or <font color="blue">enter into</font>, any <font color="blue">financing with parties</font> other than     the investors</td>
    </tr>
    <tr>
      <td>In the event that we <font color="blue">enter into</font> an <font color="blue">acquisition</font> or business <font color="blue">combination</font> in     which we sell all or <font color="blue">substantially</font> all of our assets or if there occurs a     change of control of a majority of our <font color="blue">common stock</font> outstanding prior to     <font color="blue">such transaction</font>, the holders of our series A <font color="blue">preferred stock</font> will have the     right to receive, before any <font color="blue">distribution</font>s or payments to the holders of our     <font color="blue">common stock</font>, an amount in cash equal to their <font color="blue">initial purchase price</font>,     dlra8cmam000cmam000, plus an amount equal to any <font color="blue">accrued but unpaid dividends</font>, and     will then <font color="blue">participate</font> with the holders of the <font color="blue">common stock</font> on a pro rata     basis  with  respect  to the <font color="blue">distribution</font> of any <font color="blue">remaining assets</font></td>
    </tr>
    <tr>
      <td>The     existence of this right may make it <font color="blue">difficult</font> for us to <font color="blue">raise capital</font> in     financing <font color="blue">transactions</font> with <font color="blue">third parties</font> and will also result in holders of     our <font color="blue">common stock</font> receiving less <font color="blue">distribution</font>s or <font color="blue">payments upon</font> a change of     control  or  asset  sale  than they would be entitled to receive if no     <font color="blue">preferential payments</font> were required to be made to holders of our series A     <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Regulatory Matters       If we do not obtain and maintain the <font color="blue">regulatory</font> approvals or <font color="blue">clearances</font>     required  to  market  and  sell our products, then our business may be     <font color="blue">unsuccessful</font> and the <font color="blue">market price</font> of our <font color="blue">stock may decline</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">regulation by government agencies</font> in the <font color="blue"><font color="blue">United States</font> </font>and     abroad <font color="blue">with respect</font> to the <font color="blue">manufacture</font>, packaging, labeling, <font color="blue">advertising</font>,     promotion, <font color="blue">distribution</font> and sale of our products</td>
    </tr>
    <tr>
      <td>For example, our products     are  subject  to  approval or <font color="blue">clearance by</font> the FDA prior to commercial     marketing in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Similar <font color="blue">regulations</font> exist in most major     <font color="blue">foreign markets</font>, including the <font color="blue">European Union</font>, Latin America and Asia</td>
    </tr>
    <tr>
      <td>The     process of obtaining <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals and <font color="blue">clearances</font> will be     time-consuming  and  expensive  for  us</td>
    </tr>
    <tr>
      <td>If we do not receive required     <font color="blue">regulatory</font> approval or clearance to market our products, or if any approvals     or <font color="blue">clearances</font> we have received are revoked or terminated, we may not be able     to develop and <font color="blue">commercialize</font> our products and <font color="blue">become profitable</font>, and the     value of our <font color="blue">common stock</font> may decline</td>
    </tr>
    <tr>
      <td>We are also subject to numerous foreign <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> governing     the conduct of <font color="blue">clinical trials</font>, <font color="blue">manufacturing</font> and <font color="blue">marketing authorization</font>,     pricing and third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>The foreign <font color="blue">regulatory</font> approval     process includes all of the risks associated with FDA <font color="blue">approval described</font>     above,  as  well  as  risks  <font color="blue">attributable</font> to the <font color="blue">satisfaction</font> of local     <font color="blue">regulations</font> in foreign <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>Approval by the FDA does not assure     approval by <font color="blue">regulatory</font> authorities outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Many foreign     <font color="blue">regulatory</font> authorities, including those in <font color="blue">major markets such as</font> Japan and     China, have <font color="blue">different approval procedures than</font> those required by the FDA and     may  impose  <font color="blue">additional</font>  testing  <font color="blue"><font color="blue">requirement</font>s</font>  for our medical device     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       <font color="blue">If the FDA </font>or other <font color="blue">regulatory</font> agencies place <font color="blue"><font color="blue">restrictions</font> on</font>, or impose     <font color="blue">additional</font> approval <font color="blue"><font color="blue">requirement</font>s</font> <font color="blue">with respect</font> to, products we are then     marketing, we may incur substantial <font color="blue">additional</font> costs and experience delays     or <font color="blue"><font color="blue">difficult</font>ies</font> in continuing to market and sell these products</td>
    </tr>
    <tr>
      <td>Even if the FDA grants us clearance <font color="blue">with respect</font> to marketing any product,     it may place substantial <font color="blue"><font color="blue">restrictions</font> on</font> the <font color="blue">indication</font>s for which we may     market the product, <font color="blue">which could</font> result in <font color="blue">lower revenues</font></td>
    </tr>
    <tr>
      <td>The marketing     claims we are permitted to make in labeling or <font color="blue">advertising</font> regarding our     <font color="blue">microsphere</font>s are limited to those <font color="blue">consistent with</font> any FDA clearance or     approval</td>
    </tr>
    <tr>
      <td>For example, because our <font color="blue">EmboGold Microspheres </font>are not cleared for     use in UFE, we may not <font color="blue">promote them</font> for this use</td>
    </tr>
    <tr>
      <td>We  may  in the future make <font color="blue"><font color="blue">modification</font>s</font> to our <font color="blue">microsphere</font>s or their     labeling  which  we  determine  do not <font color="blue">necessitate</font> the filing of a new     510(k) <font color="blue">notification</font></td>
    </tr>
    <tr>
      <td>However,  if  the  FDA  does  not <font color="blue">agree with</font> our     de<font color="blue">termination</font>, it will require us to make <font color="blue">additional</font> 510(k) filings for the     <font color="blue">modification</font>, and we may be <font color="blue">prohibited from marketing</font> the <font color="blue">modified product</font>     or the new claims until we obtain FDA clearance</td>
    </tr>
    <tr>
      <td>Similarly, if we obtain     <font color="blue">premarket approval</font>, we may not be able to make product or labeling changes     until we get further FDA approval</td>
    </tr>
    <tr>
      <td>Even if we obtain the <font color="blue">necessary</font> FDA <font color="blue">clearances</font> or approvals, if we or our     <font color="blue">suppliers fail</font> to <font color="blue">comply with</font> ongoing <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> our products     could be subject to <font color="blue">restrictions</font> or <font color="blue">withdrawal from</font> the market</td>
    </tr>
    <tr>
      <td>We are subject to the Medical Device Reporting, or MDR, <font color="blue">regulations</font> that     require  us  to  report  to the FDA if our <font color="blue">products may</font> have caused or     <font color="blue">contributed</font>  to  patient  death  or  serious  injury, or if our device     <font color="blue">malfunctions</font> and a recurrence of the <font color="blue">malfunction would likely</font> result in a     death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">must also file</font> reports of device <font color="blue">corrections</font> and     removals  and adhere to the FDA’s <font color="blue">rules on labeling</font> and promotion</td>
    </tr>
    <tr>
      <td>Our     failure to <font color="blue">comply with</font> these or other applicable <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>     could result in <font color="blue">enforcement</font> action by the FDA, which may include any of the     following:       ·        untitled  letters,  warning letters, fines, product seizures,     <font color="blue">injunctions</font> and <font color="blue">civil penalties</font>;       ·       <font color="blue">administrative</font> detention, which is the <font color="blue">detention by</font> the FDA of     <font color="blue">medical devices</font> believed to be <font color="blue">adulterated</font> or misbranded;       ·       customer <font color="blue">notification</font>, or FDA orders for repair, <font color="blue">replacement</font> or     refund;       ·       voluntary or <font color="blue">mandatory recall</font> or seizure of our products;       ·       operating <font color="blue">restrictions</font>, partial suspension or <font color="blue">total shutdown</font> of     production;       ·       refusal to review premarket <font color="blue">notification</font> or <font color="blue">premarket approval</font>     <font color="blue">submissions</font>;       ·       <font color="blue">rescission</font> of a substantial equivalence order or suspension or     withdrawal of a <font color="blue">premarket approval</font>; and       ·       <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>If we are subject to an <font color="blue">enforcement</font> action, our ability to develop, market     and  sell  our  <font color="blue">products <font color="blue">successfully</font></font> would be <font color="blue">adversely</font> affected, our     <font color="blue">reputation could</font> be harmed and we may experience <font color="blue">decreased market</font> <font color="blue">acceptance</font>     of our products</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       We may be subject, directly or <font color="blue">indirectly</font>, to federal and state healthcare     fraud and <font color="blue">abuse laws</font> and <font color="blue">regulations</font> and, if we are unable to <font color="blue">fully comply</font>     with such laws, could face substantial penalties</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> may be directly or <font color="blue">indirectly</font> affected by various broad state     and  federal  healthcare  fraud  and <font color="blue">abuse laws</font>, including the federal     Anti-Kickback  Statute,  which  prohibit any person <font color="blue">from knowingly</font> and     willfully offering, paying, soliciting or receiving remuneration, directly     or <font color="blue">indirectly</font>, to induce or <font color="blue">reward either</font> the referral of an individual, or     the furnishing or arranging for an item or service, for <font color="blue">which payment may</font> be     made under federal healthcare programs, such as the <font color="blue">Medicare and Medicaid     </font>programs</td>
    </tr>
    <tr>
      <td>If our past or present <font color="blue">operations</font> are found to be in violation of     these  laws,  we  or  our <font color="blue">officers may</font> be subject to civil or criminal     penalties, including large monetary penalties, damages, fines, imprisonment     and  exclusion  from  Medicare  and Medicaid <font color="blue">program participation</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">enforcement</font> action were to occur, our business and <font color="blue">financial condition</font> would     be harmed</td>
    </tr>
    <tr>
      <td>Risks Relating to Our <font color="blue">Intellectual </font>Property       If  we  are unable to obtain <font color="blue">patent protection</font> for our products, their     <font color="blue">competitive</font> value could decline</td>
    </tr>
    <tr>
      <td>We may not obtain <font color="blue">meaningful protection</font> for our <font color="blue">technology</font> and <font color="blue">products with</font>     the patents and patent <font color="blue">application</font>s that we own or license relating to our     <font color="blue">microsphere</font> <font color="blue">technology</font> or other <font color="blue">ancillary products</font></td>
    </tr>
    <tr>
      <td>In particular, the     <font color="blue">patent rights</font> we possess or are <font color="blue">pursuing <font color="blue">generally</font> cover</font> our <font color="blue">technologies</font> to     <font color="blue">varying degrees</font>, and these <font color="blue">rights may</font> not <font color="blue">prevent others from designing</font>     products  similar  to  or  otherwise  <font color="blue">competitive</font>  with our Embosphere     Microspheres and other products we <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>To the extent that our     <font color="blue">competitors</font>  are able to design products <font color="blue">competitive</font> with ours, we may     experience less market <font color="blue">penetration</font> with our products and, <font color="blue">consequently</font>, we     may have decreased revenues</td>
    </tr>
    <tr>
      <td>We do not know whether <font color="blue">competitors</font> have similar US patent <font color="blue">application</font>s on     file, since US patent <font color="blue">application</font>s filed before November 28, 2000 or for     which  no  <font color="blue">foreign patents will</font> be sought are <font color="blue">secret until issued</font>, and     <font color="blue">application</font>s filed after November 28, 2000 are published <font color="blue">approximately</font> 18     months after their <font color="blue">earliest priority date</font></td>
    </tr>
    <tr>
      <td>Consequently, the <font color="blue"><font color="blue">United States</font> </font>    Patent  and  Trademark  Office <font color="blue">could initiate <font color="blue">interference</font> <font color="blue">proceedings</font></font>     involving our owned or licensed US patent <font color="blue">application</font>s or <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Further, there is a substantial backlog of patent <font color="blue">application</font>s at the United     States Patent and Trademark Office, and the approval or rejection of patent     <font color="blue">application</font>s may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We   require  our  employees,  <font color="blue">consultants</font>  and  advisors  to  execute     <font color="blue"><font color="blue">confidential</font>ity</font>  <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>However,  we <font color="blue">cannot guarantee</font> that these     <font color="blue">agreements</font> will provide us with adequate <font color="blue">protection against</font> improper use or     <font color="blue">disclosure</font> of <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, in some situations,     these <font color="blue">agreements</font> may conflict with, or be subject to, the rights of third     parties  with  whom  our employees, <font color="blue">consultants</font> or advisors have prior     <font color="blue">employment</font> or consulting <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">others may independently</font>     develop <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font> information and <font color="blue">techniques</font>, or     <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Our failure to protect our     <font color="blue">proprietary</font> information and <font color="blue">techniques</font> may inhibit or limit our ability to     exclude certain <font color="blue">competitors</font> from the market</td>
    </tr>
    <tr>
      <td>If we become involved in expensive patent <font color="blue">litigation</font> or other <font color="blue">proceedings</font> to     enforce or defend our <font color="blue">patent rights</font>, we <font color="blue">could incur</font> substantial costs and     expenses or substantial <font color="blue">liability</font> for damages or be required to stop our     product <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> efforts</font></td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>13, 2005, we were notified of a <font color="blue">proceeding brought</font> before the     <font color="blue">European Patent Office </font>on <font color="blue">December </font>23, 2004 by <font color="blue">Biocompatibles UK Limited     </font><font color="blue">challenging</font> the <font color="blue">patentability</font> of the claims in our granted <font color="blue">European Patent     </font>1128816,  which  relates  to  certain  PVA  <font color="blue">microsphere</font>s, their use in     <font color="blue">embolization</font> and methods of <font color="blue">manufacture</font> related to such PVA <font color="blue">microsphere</font>s</td>
    </tr>
    <tr>
      <td>We     are defending our <font color="blue">European PVA </font>patent in this proceeding</td>
    </tr>
    <tr>
      <td>While we are not     able to predict the outcome of this <font color="blue">patent opposition proceeding</font>, it will     not impact our ability to sell our <font color="blue">Embosphere Microsphere </font>products</td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________       With the exception <font color="blue">of the European Opposition </font><font color="blue">proceeding just described</font>, we     are not <font color="blue">currently involved</font> in any other <font color="blue">litigation</font> or <font color="blue">actions with third</font>     parties to enforce or defend our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>However, in order to protect     or enforce our <font color="blue">patent rights</font>, we may have to initiate legal <font color="blue">proceedings</font>     against  third  parties,  such  as  <font color="blue">infringement</font> suits or <font color="blue">interference</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>By initiating legal <font color="blue">proceedings</font> to enforce our <font color="blue">intellectual</font>     <font color="blue">property rights</font>, we <font color="blue">may also provoke</font> these <font color="blue">third parties</font> to assert claims     <font color="blue">against us</font> and, as a result, our <font color="blue">patents could</font> be narrowed, invalidated or     rendered  unenforceable  by  a  court</td>
    </tr>
    <tr>
      <td>Furthermore, we may be sued for     <font color="blue">infringing on</font> the <font color="blue">intellectual</font> <font color="blue">property rights</font> of others</td>
    </tr>
    <tr>
      <td>We may find it     <font color="blue">necessary</font>, if threatened, to initiate a <font color="blue">lawsuit seeking</font> a <font color="blue">declaration from</font> a     court regarding the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property     <font color="blue">litigation</font> is costly, and, even if we prevail, could divert <font color="blue">management</font>     attention and <font color="blue">resources away from</font> our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of companies like <font color="blue">ours <font color="blue">generally</font></font> is <font color="blue">highly uncertain</font>,     <font color="blue">involves complex legal</font> and factual questions, and has <font color="blue">recently been</font> the     subject  of  much <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If we do not prevail in any <font color="blue">litigation</font>, we could be required to     pay damages, stop the <font color="blue">infringing activity</font>, or obtain a license</td>
    </tr>
    <tr>
      <td>Any required     <font color="blue">license might</font> not be available to us on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>In     addition, some <font color="blue">licenses may</font> be <font color="blue">nonexclusive</font>, and therefore, our <font color="blue">competitors</font>     may have access to the same <font color="blue">technology</font> licensed to us</td>
    </tr>
    <tr>
      <td>If we fail to obtain     a  required license or are unable to <font color="blue">design around</font> a patent, we may be     prevented  <font color="blue">from selling</font> some of our products, <font color="blue">which could</font> decrease our     revenues</td>
    </tr>
    <tr>
      <td>If any of our licenses to use third-party <font color="blue">technologies</font> in our products are     terminated, we may be unable to develop, market or sell our products</td>
    </tr>
    <tr>
      <td>We are dependent on various license <font color="blue">agreements</font> relating to each of our     current  and  <font color="blue">proposed products</font> that give us rights under <font color="blue">intellectual</font>     <font color="blue">property rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In particular, we have an <font color="blue">agreement with</font>     L’Assistance Publique-Hopitaux De Paris, pursuant to which L’Assistance     Publique-Hopitaux  De Paris has <font color="blue">granted us exclusive rights</font> to use two     jointly owned patents relating to <font color="blue">Embosphere Microspheres</font></td>
    </tr>
    <tr>
      <td>We also have an     <font color="blue">agreement with</font> Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Shinichi Hori </font>pursuant to which we have an exclusive     royalty-bearing  license  to Japanese <font color="blue">patent rights</font> for our HepaSphere     Microsphere product</td>
    </tr>
    <tr>
      <td>We also have an <font color="blue">agreement with</font> Archimmed SARL pursuant     to which we have an exclusive royalty-bearing license to <font color="blue">patent rights</font> for     our MR-<font color="blue">Embosphere Microsphere </font>product, which is in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Each of     these <font color="blue">agreements</font> can be terminated on short notice by the licensor if we     default on our <font color="blue">obligations</font> under the license and fail to cure such default     after  notice  is  provided</td>
    </tr>
    <tr>
      <td>These licenses impose <font color="blue">commercialization</font>,     sublicensing, royalty, insurance and other <font color="blue">obligations</font> on us</td>
    </tr>
    <tr>
      <td>Our failure,     or any third party’s failure, to <font color="blue">comply with</font> the terms of any of these     <font color="blue">licenses could</font> result in our losing our rights to the license, <font color="blue">which could</font>     result in our being unable to develop, <font color="blue">manufacture</font> or <font color="blue">sell products which</font>     contain the licensed <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Risks Relating to the Production and Supply of Our Products       If we experience <font color="blue">manufacturing</font> delays or <font color="blue">interruptions</font> in production, then     we may experience customer dis<font color="blue">satisfaction</font> and our <font color="blue">reputation could</font> suffer</td>
    </tr>
    <tr>
      <td>If we fail to produce <font color="blue">enough <font color="blue">products at</font></font> our own <font color="blue">manufacturing</font> <font color="blue">facility</font> or     at  a  third-party <font color="blue">manufacturing</font> <font color="blue">facility</font>, we may be unable to deliver     products to our customers on a timely basis, <font color="blue">which could</font> lead to customer     dis<font color="blue">satisfaction</font> and <font color="blue">could harm</font> our reputation and ability to compete</td>
    </tr>
    <tr>
      <td>We     currently  produce  and package all of our <font color="blue">microsphere</font> products in one     <font color="blue">manufacturing</font> <font color="blue">facility</font> in France</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we have engaged     Radius  Medical Technologies, Inc</td>
    </tr>
    <tr>
      <td>to supply our <font color="blue">guidewire product</font> and     <font color="blue">Concert Medical </font>to supply and package our catheter product</td>
    </tr>
    <tr>
      <td>Either we or any     third-party <font color="blue">manufacture</font>r would likely experience <font color="blue">significant</font> delays or     cessation in producing our products if a labor strike, natural disaster,     local or <font color="blue">regional conflict</font> or other <font color="blue">supply <font color="blue">disruption</font></font> were to occur</td>
    </tr>
    <tr>
      <td>If we     are unable to       29     ______________________________________________________________________       <font color="blue">manufacture</font> and package our <font color="blue">products at</font> our <font color="blue">facility</font> in France, we may be     required to <font color="blue">enter into</font> arrangements with one or more <font color="blue">alternative</font> contract     <font color="blue">manufacturing</font> companies</td>
    </tr>
    <tr>
      <td>Even if we are able to identify <font color="blue">alternative</font> facilities to <font color="blue">manufacture</font> our     products, if <font color="blue">necessary</font>, we may experience <font color="blue">disruption</font> in the supply of our     <font color="blue">products until such facilities</font> are available</td>
    </tr>
    <tr>
      <td>Although we believe we possess     <font color="blue">adequate insurance</font> for damage to our property and the <font color="blue">disruption</font> of our     business from casualties, such insurance may not be sufficient to cover all     of our <font color="blue">potential losses</font> and may not be available to us on acceptable terms     or at all</td>
    </tr>
    <tr>
      <td>Our failure to deliver <font color="blue">products on</font> a <font color="blue">timely basis could lead</font> to     customer dis<font color="blue">satisfaction</font> and damage our reputation</td>
    </tr>
    <tr>
      <td>In addition, if we are     required to depend on third-party <font color="blue">manufacture</font>rs, our <font color="blue">profit margins may</font> be     lower, which will make it more <font color="blue">difficult</font> for us to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Medical device <font color="blue">manufacture</font>rs must adhere to the Quality System Regulation,     or QSR, 21 <font color="blue">Code of Federal Regulation Part </font>820, which is <font color="blue">enforced by</font> the FDA     through its <font color="blue">inspection program</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>rs may not be able to comply     or maintain compliance</td>
    </tr>
    <tr>
      <td>If any third-party <font color="blue">manufacture</font>rs we engage fail to     comply, their <font color="blue">noncompliance</font> could <font color="blue"><font color="blue">significant</font>ly</font> delay our receipt of new     product <font color="blue">premarket approval</font>s or result in FDA <font color="blue">enforcement</font> action, including     an <font color="blue">embargo on imported devices</font></td>
    </tr>
    <tr>
      <td>For a <font color="blue">premarket approval</font> device, if we     change our <font color="blue">manufacturing</font> <font color="blue">facility</font> or switch to a third-party <font color="blue">manufacture</font>r,     we will be required to submit a <font color="blue">premarket approval</font> <font color="blue">application</font> supplement     before the change is implemented</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  rely  on a limited number of suppliers, we may experience     <font color="blue"><font color="blue">difficult</font>y</font> in meeting our customers’ demands for our products in a timely     manner or <font color="blue">within budget</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">currently purchase key <font color="blue">components</font></font> and services <font color="blue">with respect</font> to our     <font color="blue">microsphere</font>s, <font color="blue">catheters</font> and guidewires from <font color="blue">approximately</font> nine third-party     vendors, including Radius Medical, from whom we <font color="blue">purchase guidewires</font> for our     Segway  Guidewire  product, and Concert Medical, from whom we purchase     <font color="blue">catheters</font> for our EmboCath Infusion Catheters product</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> do not     have long-term <font color="blue">agreements</font> with any of our suppliers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> our     suppliers exposes us to risks, including:       •     the <font color="blue">possibility</font> that one or more of our <font color="blue">suppliers could terminate</font>     their <font color="blue">services at</font> any time <font color="blue">without penalty</font>;       •      the  potential  <font color="blue">inability</font>  of  our suppliers to obtain required     <font color="blue">components</font>;       •     the <font color="blue">potential delays</font> and expenses of seeking <font color="blue">alternative</font> sources of     supply;       •     reduced control over pricing, quality and <font color="blue">timely delivery due</font> to     <font color="blue"><font color="blue">difficult</font>ies</font> in switching to <font color="blue">alternative</font> suppliers; and       •     the <font color="blue">possibility</font> that one or more of our <font color="blue">suppliers could fail</font> to be     <font color="blue">compliant with</font> Quality System Regulations, 21 CFR Part 820</td>
    </tr>
    <tr>
      <td>Consequently, in the event that our <font color="blue">suppliers delay</font> or interrupt the supply     of <font color="blue">components</font> for any reason, our ability to produce and supply our products     could be impaired, <font color="blue">which could</font> lead to customer dis<font color="blue">satisfaction</font> and be     harmful to our reputation</td>
    </tr>
    <tr>
      <td>Risks Relating to Our Foreign Operations       If we are unable to meet the operational, legal and <font color="blue">financial <font color="blue">challenges</font></font>     that we encounter in our <font color="blue">international</font> <font color="blue">operations</font>, we may not be able to     grow our business</td>
    </tr>
    <tr>
      <td>Our worldwide <font color="blue">manufacturing</font> and European sales <font color="blue">operations</font> are currently     <font color="blue">conducted primarily through</font> our French subsidiary</td>
    </tr>
    <tr>
      <td>Furthermore, we currently     derive a portion of our <font color="blue">revenues from</font> the sale of our <font color="blue">microsphere</font>s and other     products in the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>For the years ended <font color="blue">December </font>31, 2005       30     ______________________________________________________________________       and 2004, <font color="blue">approximately</font> 27prca and 30prca, respectively, of our revenues were     <font color="blue">derived from</font> sales of our <font color="blue">microsphere</font>s and other products in the European     Union</td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">increasingly</font>  subject  to a number of <font color="blue">challenges</font> that     <font color="blue">specifically</font>  relate  to  our  <font color="blue">international</font>  business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">international</font> <font color="blue">operations</font> may not be successful if we are unable to meet and     overcome these <font color="blue">challenges</font>, which would limit the growth of our business</td>
    </tr>
    <tr>
      <td>These <font color="blue">challenges</font> include:       •     failure of <font color="blue">local laws</font> to provide the same degree of <font color="blue">protection against</font>     <font color="blue">infringement</font> of our <font color="blue">intellectual</font> property;       •      <font color="blue">protectionist</font>  laws  and  business  practices  that <font color="blue">favor local</font>     <font color="blue">competitors</font>, <font color="blue">which could</font> slow our growth in <font color="blue">international</font> markets;       •    the <font color="blue">requirement</font> that we obtain <font color="blue">regulatory</font> approval or clearance in each     country in which we choose to offer and sell our products;       •    in some <font color="blue">jurisdictions</font>, strict government regulated price controls;       •     complex <font color="blue">reimbursement</font> proedures;       •     <font color="blue">potentially longer sales cycles</font> to sell products, <font color="blue">which could</font> slow our     revenue growth from <font color="blue">international</font> sales; and       •     potentially longer accounts receivable payment cycles and <font color="blue"><font color="blue">difficult</font>ies</font>     in <font color="blue">collecting accounts receivable</font></td>
    </tr>
    <tr>
      <td>Because we translate <font color="blue">foreign currency</font> from <font color="blue">international</font> sales into US     dollars and are required to make <font color="blue"><font color="blue">foreign currency</font> payments</font>, we may incur     losses due to <font color="blue">fluctuations</font> in <font color="blue"><font color="blue">foreign currency</font> exchange rates</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our business is conducted in the <font color="blue"><font color="blue">European Union</font> </font>    Euro</td>
    </tr>
    <tr>
      <td>We  recognize <font color="blue"><font color="blue">foreign currency</font> gains</font> or losses arising from our     <font color="blue">operations</font>  in the <font color="blue">period incurred</font></td>
    </tr>
    <tr>
      <td>As a result, currency <font color="blue">fluctuations</font>     between the US dollar and the currencies in which we do business will     cause  foreign  <font color="blue">currency translation gains</font> and losses, which may cause     <font color="blue">fluctuations</font> in our future operating results</td>
    </tr>
    <tr>
      <td>We do not currently engage in     foreign  exchange  hedging <font color="blue">transactions</font> to manage our <font color="blue">foreign currency</font>     exposure</td>
    </tr>
    <tr>
      <td>Risk Relating to Our Stock Price       Because the <font color="blue">market price</font> of our stock is <font color="blue">highly volatile</font>, <font color="blue">investment</font>s in our     stock could rapidly lose their value and we may incur <font color="blue">significant</font> costs from     class action <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our stock is <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">From January </font>1, 2004     through March 1, 2006, the price of our <font color="blue">common stock</font> has <font color="blue">ranged from</font> a low     of dlra2dtta12 to a high of dlra9dtta43</td>
    </tr>
    <tr>
      <td>As a result of this <font color="blue">volatility</font>, <font color="blue">investment</font>s in     our stock could rapidly lose their value</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font>     often experiences <font color="blue">extreme price</font> and volume <font color="blue">fluctuations</font>, which affect the     <font color="blue">market price</font> of many medical device companies and which are <font color="blue">often unrelated</font>     to the operating performance of these companies</td>
    </tr>
    <tr>
      <td>When the <font color="blue">market price</font> of a stock has <font color="blue">been as volatile as</font> our stock price has     been, holders of that <font color="blue">stock may institute securities</font> class action <font color="blue">litigation</font>     against the company that issued the stock</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">stockholders</font> were     to bring a lawsuit of this type <font color="blue">against us</font>, even if the lawsuit is without     merit,  we <font color="blue">could incur</font> substantial costs in defending the lawsuit</td>
    </tr>
    <tr>
      <td>The     <font color="blue">lawsuit could also divert</font> the time and attention of our <font color="blue">management</font></td>
    </tr>
  </tbody>
</table>